Boston

Special Report

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

By Eric Boodman

Health

Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again

By Andrew Joseph

Adam's Take

Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

By Adam Feuerstein

Biotech

In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval

By Matthew Herper

Biotech

This small biotech is suing the Trump administration to get its drug covered

By Nicholas Florko

Health

New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients

By Andrew Joseph

Health

Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing

By Sharon Begley

Biotech

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

By Jonathan Saltzman — Boston Globe

Biotech

Alexion acquiring Achillion to expand reach into rare, immune-related disease

By Adam Feuerstein

Biotech

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

By Jonathan Saltzman — Boston Globe

Pharma

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

By Damian Garde

In the Lab

Three scientists win Nobel Prize in medicine for discovering how cells sense and adapt to oxygen levels

By Sharon Begley

Biotech

These 4 biotechs are already bragging about their ‘Nobel Prize-winning’ bona fides

By Kate Sheridan

Biotech

Sarepta gene therapy improves muscle function for patients with rare limb-girdle disease

By Adam Feuerstein

In the Lab

Growing tumors in a dish, scientists try to personalize pancreatic cancer treatment

By Karen Weintraub

Biotech

Sarepta under new pressure as a competitor files with FDA for Duchenne drug

By Adam Feuerstein

Biotech

They got Pfizer’s ‘Golden Ticket.’ Did it live up to the hype?

By Kate Sheridan

Biotech

At Biogen, drug developer Al Sandrock gets a chance to take his shot

By Matthew Herper

Biotech

Biotech incubator LabCentral to double its space in Boston

By Jonathan Saltzman — Boston Globe

Biotech

Vertex takes on Huntington’s disease in deal with Ribometrix

By Jonathan Saltzman — Boston Globe

Health

Watch: In a quest for more precise cancer care, hospitals invest in new tools — and new training, too

By Megan Thielking

Biotech

Moderna will give Harvard researchers access to its RNA technology

By Kate Sheridan

Business

Bayer to invest in Boston lab focused on chronic lung conditions

By Jonathan Saltzman — Boston Globe

Biotech

Akcea, a biotech that relies on gene-blocking tech, loses its three top executives in one fell swoop

By Kate Sheridan

Biotech

RA Capital launches Carnot, an incubator for early-stage biotechs

By Kate Sheridan

‘A game-changer’: How Vertex delivered on cystic fibrosis

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

7 burning questions now that Biogen has resurrected its ‘failed’ Alzheimer’s drug

Experts parse Biogen’s Alzheimer’s data: Does the treatment work, or is it a mirage?

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again

Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval

This small biotech is suing the Trump administration to get its drug covered

New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients

Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

Alexion acquiring Achillion to expand reach into rare, immune-related disease

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?

Three scientists win Nobel Prize in medicine for discovering how cells sense and adapt to oxygen levels

These 4 biotechs are already bragging about their ‘Nobel Prize-winning’ bona fides

Sarepta gene therapy improves muscle function for patients with rare limb-girdle disease

Growing tumors in a dish, scientists try to personalize pancreatic cancer treatment

Sarepta under new pressure as a competitor files with FDA for Duchenne drug

They got Pfizer’s ‘Golden Ticket.’ Did it live up to the hype?

At Biogen, drug developer Al Sandrock gets a chance to take his shot

Biotech incubator LabCentral to double its space in Boston

Vertex takes on Huntington’s disease in deal with Ribometrix

Watch: In a quest for more precise cancer care, hospitals invest in new tools — and new training, too

Moderna will give Harvard researchers access to its RNA technology

Bayer to invest in Boston lab focused on chronic lung conditions

Akcea, a biotech that relies on gene-blocking tech, loses its three top executives in one fell swoop

RA Capital launches Carnot, an incubator for early-stage biotechs